CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 突触成像作为 CAR 工程的质量控制
英文原题：Imaging CAR-T Synapse as a Quality Control for CAR Engineering.
查看英文原题
Imaging CAR-T Synapse as a Quality Control for CAR Engineering.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）已发展成为重编程T细胞以实现靶向杀伤的强大工具。CAR-T 疗法在治疗某些类型的血液肿瘤中取得了成功，其应用目前正扩展至实体瘤、自身免疫性疾病、病毒感染和纤维化。这些应用需要设计大量靶向多种抗原的新型CAR。在此，我们描述了两种作为新开发CAR验证质量控制的方法：（1）细胞间偶联实验，反映CAR在细胞环境中与抗原的有效结合；（2）突触中CD45的排除，作为CAR信号传导潜力的指示。这些实验检测了功能性CAR-T 的先决条件，并揭示了CAR-T 激活无效的原因。
展开英文摘要原文
The chimeric antigen receptor (CAR) evolves as a powerful tool to reprogram T cells for targeted killing. CAR-T therapy succeeded in treating certain types of blood cancers, and its application is now expanding towards solid tumors, autoimmune diseases, viral infection, and fibrosis. These require the design of a large number of new CARs that target a variety of antigens.
Here we described two methods as a quality control for validating newly developed CARs: (1) the cell-cell conjugation assay as a reflection of efficient binding of CAR to antigen in the cellular context and (2) CD45 exclusion in the synapse as an indication of CAR signaling potential. These assays examine prerequisites for a functional CAR-T and reveal causes for ineffective CAR-T activation.
论文信息
- 作者
- Xiao Q、Su X
- 第一作者单位
- Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA.United States
- 通讯作者单位
- Department of Cell Biology, Yale School of Medicine, New Haven, CT, USA. xiaolei.su@yale.edu.United States
- 期刊
- Methods in molecular biology (Clifton, N.J.)2023
- 原文标识
- PubMed 37106204 · DOI 10.1007/978-1-0716-3135-5_33
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →